Financial Performance - Total revenue for the first quarter of 2022 reached HKD 384,157,000, a significant increase of 149.0% compared to HKD 154,169,000 in the same period last year[9] - Gross profit for the first quarter was HKD 189,732,000, representing a gross margin of 49.3% compared to 48.8% in the previous year[9] - Operating profit increased to HKD 133,261,000, up 242.5% from HKD 38,865,000 year-over-year[9] - Profit before tax for the quarter was HKD 132,044,000, a rise of 261.5% compared to HKD 36,585,000 in the prior year[9] - Net profit for the period was HKD 106,585,000, compared to HKD 27,239,000 in the same quarter last year, marking a growth of 290.5%[9] - Basic and diluted earnings per share increased to HKD 0.036, up from HKD 0.002 in the previous year[11] - The company reported a total comprehensive income of HKD 75,030,000 for the quarter, compared to HKD 26,746,000 in the same period last year[11] Revenue Breakdown - For the three months ended March 31, 2022, the revenue from medical laboratory testing and health check services was HKD 162,662 thousand, an increase from HKD 146,440 thousand in the same period of 2021, representing a growth of 11.5%[27] - The revenue from the manufacturing and sales of health-related and pharmaceutical products reached HKD 214,752 thousand, significantly up from HKD 107 thousand in the previous year, indicating a substantial increase[27] - Total income from securities trading amounted to HKD 384,088 thousand, compared to HKD 154,169 thousand in the same period last year, reflecting a growth of 149.5%[27] Expenses and Costs - Administrative expenses rose to HKD 54,340,000, compared to HKD 33,419,000 in the previous year, reflecting increased operational costs[9] - The company’s interest expenses for the first quarter of 2022 totaled HKD 1,217,000, down from HKD 2,280,000 in the first quarter of 2021[7] - The effective tax expense for the first quarter of 2022 was HKD 25,459,000, compared to HKD 9,346,000 in the same period of 2021[32] Market and Operational Developments - The company continues to focus on expanding its medical laboratory and health services in Hong Kong and China[18] - The demand for diagnostic and health check services surged due to the COVID-19 fifth wave, prompting the company to reactivate its fire eye laboratory for community testing[73] - The company anticipates a rebound in demand for self-paid nucleic acid testing and other medical diagnostic services as entry restrictions ease[73] - The company’s subsidiary, Shanghai Longyao, received approval for its CAR-T therapy product, LY007, to commence Phase I clinical trials, marking a significant advancement in its product pipeline[48] Share Capital and Ownership - As of March 31, 2022, the total issued share capital of the company was 963,231,150 shares, with a par value of HKD 0.10 per share[89] - Genius Earn holds a controlling interest with 529,500,546 shares, representing 54.97% of the total shares[19] - The total issued shares of the company as of March 31, 2022, is 963,231,150 shares[94] - Guoyuan Securities Investment (Hong Kong) holds 22,428,571 shares, accounting for 2.33% of the total shares[19] Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the financial reporting procedures and internal controls for the first quarter of 2022[121] - The company emphasizes the importance of corporate governance and has implemented measures to ensure compliance with legal and regulatory requirements[118] - The company confirmed that all directors adhered to the trading standards and conduct codes during the first quarter of 2022[117] Strategic Initiatives - The company signed a non-binding term sheet for an investment of RMB 20,000,000 with an investor on January 26, 2022, although no formal agreement has been established yet[66] - A supplemental supply agreement was signed on February 15, 2022, increasing the annual cap for related transactions from HKD 80,000,000 to HKD 400,000,000, covering the supply of COVID-19 rapid antigen test kits[67] - The company established a joint venture with Sure Metro Limited, acquiring 51% and 49% stakes respectively, to operate a medical laboratory in Hong Kong[70]

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 2021 精準治療 PRECISION TREATMENT 精準檢測 PRECISION DIAGNOSIS 未來生物科技平臺 FUTURE BIOTECHNOLOGY PLATFORM 精準檢測 PRECISION DIAGNOSIS 未來生物科技平臺 FUTURE BIOTECHNOLOGY PLATFORM 年 報 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有較高投資風險。 有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場 ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) Stock Code: 8037 Precision Treatment 精準治療 Precision Diagnosis 精準檢測 Future Biotechnology Platform 未來生物科技平臺 THIRD QUARTERLY REPORT 2021 2021 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 Precision Treatment 精準治療 Precision Diagnosis 精準檢測 Future Biotechnology Platform 未來生物科技平臺 第三季度業績報 告 01 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司 ...

中期報告 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) Stock Code: 8037 INTERIM REPORT 2021 Precision Diagnosis 精準檢測 Future Biotechnology Platform 未來生物科技平臺Precision Treatment 精準治療 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 2021 中身 Future Biotechnology Platform 未來生物科技平臺Precision Treatment 精準治療 Precision Diagnosis 精準檢測 ...

Future Biotechnology Platform 未來生物科技平臺 Future Biotechnology Platform 未來生物科技平臺 Precision Diagnosis 精準檢測 Precision Treatment 精準治療 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) Stock Code: 8037 Precision Diagnosis 精準檢測 Precision Treatment 精準治療 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 C 9 C 01 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有 較高投資風險。 ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 • 精準檢測 • Precision Diagnosis • 未來生物科技平臺 • Future Biotechnology Platform • 精準治療 • Precision Treatment 年報 2020 NH NF 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有較高投資風險。 有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波動風險， 同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交 ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (於開曼群島註冊成立並在百慕達繼續營業之有限公司) 股份代號: 8037 第三季度業績報 告 2020 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有 較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後 方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的 市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 本報告的資料乃遵照《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關中國生物科技 服務控股有限公司（「本公司」）的資料；本公司的董事（「董事」）願就本報告的資料共同及個別地承 擔全部責任。各董事在作出一切合 ...

CHIMA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (MUSELS E-RED MENT COST Future Biotechnology Platform Precision Diagnosis 呼堆檢測 Precision Treatment 精準治療 2020 中期報告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在主板上市的公司帶有 較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後 方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的 市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 本報告的資料乃遵照《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關中國生物科技 ...

| --- | --- | --- | --- | --- | |---------------------------------------------------|-------|-------|---------------------|-------| | | | | | | | | | | | | | | | | | | | Precision Treatment Future Biotechnology Platform | | | Precision Diagnosis | | | 精準治療 未來生物科技平臺 | | | 精準檢測 | | Future Biotechnology Platform 未來生物科技平臺 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) Stock Code: 8037 第一季度業績報告 2020 First Quarterly Repor ...

ANNUAL REPORT 2019 年 報 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 | --- | --- | --- | --- | --- | --- | |-------|-------------------------------------|----------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | | | | | | | CHINA BIOTECH SERVICES HOLDINGS LIMITED CHINA BIOTECH SERVICES HOLDINGS LIMITED | | | | ( ( 股份代號 : 8037 股份代號 : ...